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Background: The fraction of exhaled nitric oxide (FeNO) has been suggested as a non-invasive marker of eosinophilic
inflammation in asthma, but lately rather as a biomarker of atopy than of asthma itself. Asthma after bronchiolitis is
common up to early adolescence, but the inflammation and pathophysiology may differ from other phenotypes
of childhood asthma. We aimed to assess if FeNO was different in children with former hospitalization for
bronchiolitis and a control group, and to explore whether the role of FeNO as a marker of asthma, atopy or
bronchial hyperresponsiveness (BHR) differed between these two groups of children.
Methods: The study included 108 of 131 children (82%) hospitalized for bronchiolitis in 1997–98, of whom
82 (76%) had tested positive for Respiratory syncytial virus, and 90 age matched controls. The follow-up took
place in 2008–2009 at 11 years of age. The children answered an ISAAC questionnaire regarding respiratory
symptoms and skin prick tests, spirometry, methacholine provocation test and measurement of FeNO were
performed.
Results: Analysed by ANOVA, FeNO levels did not differ between the post-bronchiolitis and control groups (p = 0.214).
By multivariate regression analyses, atopy, height (p < 0.001 for both) and BHR (p = 0.034), but not asthma (p = 0.805) or
hospitalization for bronchiolitis (p = 0.359), were associated with FeNO in the post-bronchiolitis and control groups. The
associations for atopy and BHR were similar in the post-bronchiolitis and in the control group.
Conclusion: FeNO did not differ between 11 year old children hospitalized for bronchiolitis and a control group. FeNO
was associated with atopy, but not with asthma in both groups.
Keywords: Children, Eosinophilic inflammation, Respiratory syncytial virus, WheezingBackground
Asthma in childhood is characterized by extensive het-
erogeneity regarding aetiology and natural history, and
may present with various phenotypes probably related
to different immunological, inflammatory and airway
characteristics [1]. Chronic inflammation of the lower
airways and bronchial hyperresponsiveness (BHR) are
typical features of asthma, and markers of these factors
are therefore used for diagnostic purposes and to guide
treatment. The fraction of exhaled nitric oxide (FeNO) has
been suggested as a non-invasive marker of eosinophilic
inflammation [2], and thus a marker of asthmatic airway
inflammation. Recently, FeNO has been suggested as a bio-
marker of atopy, and thereby a biomarker of atopic asthma* Correspondence: miib@sus.no
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reproduction in any medium, provided the orrather than of asthma per se [3-5], although findings have
been equivocal [6-8]. Associations between FeNO and
BHR, but not between FeNO and asthma have been
described in atopic children [5].
Bronchiolitis in early life is an established risk factor
for subsequent asthma, although the mechanisms behind
are complex and heterogeneous [9]. The risk of asthma is
higher after RSV negative than RSV positive bronchiolitis
[10], particularly after early wheezing or bronchiolitis due
to Rhinovirus (RV) [11]. While atopic asthma is associated
with an eosinophilic inflammation, asthma after bronchio-
litis is less related to atopy and mainly associated with viral
induced wheeze and bronchial inflammation mediated by
neutrophils [12-14]. Thus, markers of inflammation such
as FeNO could conceivably be different in asthma after
bronchiolitis than in children with atopic asthma.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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was different in children with former hospitalization for
bronchiolitis compared to a control group, and secondly
to explore whether the role of FeNO as a marker of
asthma, atopy or BHR differed between these two groups
of children.
Methods
Study design and subjects
In this longitudinal prospective follow-up study, children
below 12 months of age hospitalized for acute bronchio-
litis at the university hospitals in Stavanger and Bergen
(Norway) during the winter seasons 1997 and 1998 were
invited to participate. Bronchiolitis was defined as an acute
febrile episode of respiratory illness with tachypnea,
dyspnoea, prolonged expiration and wheeze on auscultation
of the chest. Exclusion criteria were previous hospitalization
for wheeze or bronchiolitis, any previous use of systemic
or inhaled corticosteroids, signs of bacterial infection or
any other known lung disease [15]. Nasopharyngeal mucus
was examined for Respiratory syncytial virus (RSV) by
direct immunofluorescence in all patients (bioMèrieux,
Marcy-l’Ètoile, France). Other viruses were not systematic-
ally tested for.
The children were invited to a follow-up in 2008–09 at
11 years of age. The follow-up included a questionnaire
from the International Study of Asthma and Allergy in
Childhood (ISAAC) [16], assessment of lung function and
BHR, FeNO measurement and skin prick tests (SPT). An
unselected age matched control group not hospitalized for
bronchiolitis during their first year of life, reflecting the
general population in the study area was recruited from 3
nearby schools.
We have previously published results showing that
children in the post-bronchiolitis group had more
asthma, lower lung function and higher BHR compared to
controls [10].
The study was approved by the Regional Committee
for Medical and Health Research Ethics West, and signed
statements of informed consent were obtained from all
parents.
Lung function measurements
Spirometry was performed according to established guide-
lines [17], using a Vmax Encore 229D spirometer (Sensor-
Medics Inc., Anaheim, USA). Forced expiratory volume in
first second (FEV1), forced vital capacity (FVC) and forced
expiratory flows at 25-75% of FVC (FEF25-75) were re-
corded. Except for the ratio FEV1/FVC, measurements
were compared to values predicted by standard reference
equations and expressed as percentages of predicted FEV1%
[18] and FEF25-75% [19]. BHR was assessed with metha-
choline provocation test (MPT), by using an inhalation-
synchronised, dosimetric nebulizer, Spira Elektra 2® (Spira,Hämeenlinna, Finland). The test was not performed if
baseline FEV1% was <65% predicted. Methacholine was
administered in doubling doses until a 20% reduction in
FEV1 was obtained or until a cumulative dose of 11.54 μmol
had been given. A dose response slope (DRS) was cal-
culated as the ratio between the maximum percentage
decline in FEV1 from baseline and the total administered
dose of methacholine (%/μmol), and the distribution
regarded as ln-normal [20].
FeNO measurements
FeNO was measured online by the single breath technique
according to published guidelines [21], with an EcoMedics
Exhalyzer ® CLD 88sp with DENOX 88 (ECO MEDICS
AG, Duernten, Switzerland). NO-free air was inhaled to
near total lung capacity, followed immediately by full ex-
halation at a constant flow of 50 ml/s. FeNO was recorded
as the mean value from 3 reproducible plateaus within 10%
acceptability.
Skin prick tests
Skin prick tests (SPT) with the most common inhalant
allergens (Dermatophagoides pteronyssinus, dog, cat dander,
Cladosporium herbarium, birch, timothy, German cock-
roach) and food allergens (eggwhite, milk, peanut, codfish)
(Soluprick®, ALK Albello, Hørsholm, Denmark) for atopic
sensitization in Norwegian children were performed [22].
Histamine 10 mg/ml was used as a positive control and a
0.9% saline solution as a negative control. A wheal diam-
eter ≥ 3 mm larger than the negative control was defined
as a positive result.
Definitions
Current asthma at 11 years of age was defined as a positive
answer to the ISAAC question regarding “asthma ever” and
a positive answer to at least one of the two questions:
1) wheezing or whistling in the chest or chest tightness
during the preceding 12 months or 2) use of asthma medi-
cation (bronchodilators, inhaled corticosteroid, leukotriene
antagonists) during the preceding 12 months.
The children in the post-bronchiolitis and control groups
were divided into four sub-groups at the 11 year follow-up,
according to their atopic and asthmatic status. 1) Healthy:
No current asthma and no allergic sensitization. 2) Atopic
non-asthmatic: Positive SPT for at least one allergen with
the absence of current asthma. 3) Current atopic asthma:
A combination of current asthma and atopy. 4) Current
non-atopic asthma: Current asthma without atopy.
Statistical methods
Means and standard deviations (SD), medians and quartiles
were estimated and reported for normally and asymmetric-
ally distributed data, as appropriate. Group comparisons
were done with Student’s t- test, Mann Whitney U-test or
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parts per billion (ppb)) was regarded as ln-normally dis-
tributed and results presented as back-transformed values
given as geometric means with 95% confidence intervals
(CI). To study overall associations with FeNO, a two-way
ANOVA was performed for the post-bronchiolitis and
control groups in one common analysis. To study associa-
tions with FeNO for each sub-group, the post-bronchiolitis
and control groups were analysed separately and Dunnett’s
test was used for post-hoc comparisons between the sub-
groups if the F-test was significant in the overall ANOVA
analysis.
Linear regression analyses were applied to explore
associations between putative explanatory variables and ln
FeNO for the complete study group and for the post-
bronchiolitis group separately. In both models, the follow-
ing variables recorded at 11 years of age were assessed:
Gender, age at follow-up, height, weight, atopy, current
asthma, ln DRS, FEV1%, FEF25–75%, use of inhaled steroids
the preceding 12 months and previous hospitalization
for bronchiolitis in infancy. In the separate multivariate
linear regression analysis including only subjects in the
post-bronchiolitis group, RSV status (positive or nega-
tive) was also included in addition to those included for
the complete study group. In all analyses, each variable
was initially entered into a univariate model. Variables with
p-values < 0.2 in univariate analyses were further analysed
in a backward multivariate regression model. Analyses of
interaction terms were used to explore differences between
the sub-groups regarding associations between explanatory
variables and FeNO. When ln transforming DRS, negative
values were set to 0.001. P-values < 0.05 were regarded as
statistically significant. All analyses were two-tailed and
data were analyzed using the SPSS version 18.0 statistical
package (SPSS, Chicago, IL, USA).Table 1 Characteristics of 108 children hospitalized for bronc
university hospitals of Stavanger and Bergen (Norway) accord
Healthy
(n = 64)
Atopic
non-asthmatic (n = 20)
Boys, n (% of group) 30 (47) 14 (70)
Age at hospitalization* (months) 3.5 (2.0, 6.0) 4.0 (1.0, 10.0)
Age at follow up* (year) 11.4 (11.0, 11.8) 11.3 (10.9, 11.5)
Weight at follow-up† (kg) 41.2 (9.3) 40.6 (8.2)
Height at follow-up† (cm) 149.0 (8.2) 147.2 (4.3)
ICS, n (% of group) 0 0
FEV1%
† 93.9 (9.3) 99.7 (8.9)
FEF25–75%
† 89.9 (23.9) 88.6 (19.1)
FEV1 /FVC ratio
† 82.8 (7.5) 80.6 (4.9)
DRS to methacholine* 6.0 (1.7, 25.5) 4.9 (1.1, 13.4)
*Median (inter quartile range), †mean (standard deviation). ICS, inhalation corticoste
second as percentage of predicted; FEF25–75%, forced expiratory flow between 25-7
data, see text. P-values assess comparisons with the healthy group.
Bold values indicate significance at the 0.05 level.Results
One hundred and thirty one children hospitalized for
bronchiolitis during their first year of life were included,
and 108 (82%) consented to the follow-up at 11 years of
age. Of these, 82 children (76%) had tested positive for
RSV. All completed the questionnaire and took part in
SPT and lung function tests. MPTand FeNO were not per-
formed in two and three children in the post-bronchiolitis
group respectively, due to technical reasons.
In the control group, 91 of the 190 primarily invited
children (48%) completed the questionnaire and agreed to
SPT and lung function test; one was excluded as further
investigations indicated chronic restrictive lung disease.
One child was not able to perform neither spirometry,
FeNO nor MPT. In addition, MPT was not performed in
two children; one had FEV1% < 65% and one was not able
to cooperate.
In the post-bronchiolitis group, FEV1% was lower in
the healthy group compared to the atopic non-asthmatic
group (Tables 1 and 2). There were no other differences
between the four sub-groups regarding gender, age, weight,
height, lung function and BHR at the 11 year follow-up
within the post-bronchiolitis group and the control group,
respectively (Tables 1 and 2).
Children in the post-bronchiolitis group (11.4 years; 11.0,
11.7) (median; quartiles) were slightly younger than the
controls (11.7 years; 11.3, 12.1) at the 11 year follow-up
(p < 0.001).
FeNO
The overall ANOVA analysis with all children included,
revealed that FeNO levels did not differ between the
post-bronchiolitis and control groups (p = 0.214) (Table 3).
FeNO differed between the four sub-groups (p < 0.001).
FeNO levels were higher in the atopic non-asthmatic andhiolitis in their first year of life during 1997–98 at the
ing to asthma and atopy at 11 years of age
P-value Current non-atopic
asthma (n = 15)
P-value Current atopic
asthma (n = 9)
P-value
0.080 10 (67) 0.252 6 (67) 0.308
0.603 6.0 (3.0, 9.0) 0.052 5.0 (4.0, 9.5) 0.083
0.182 11.4 (10.9, 11.6) 0.745 11.6 (11.3, 12.2) 0.410
0.791 42.8 (7.5) 0.525 42.5 (8.3) 0.692
0.206 149.3 (5.6) 0.888 148.9 (6.0) 0.963
2 (13) 0.034 7 (78) <0.001
0.014 97.8 (9.5) 0.145 95.8 (9.5) 0.555
0.819 86.0 (22.9) 0.568 84.4 (20.2) 0.514
0.221 79.7 (7.7) 0.159 78.8 (7.3) 0.135
0.378 4.1 (1.5, 18.1) 0.910 4.4 (2.2, 13.8) 0.923
roid last 12 months before follow up; FEV1%, forced expiratory volume in first
5% of the forced vital capacity (FVC); DRS, dose response slope. For missing
Table 2 Characteristics of 90 children in an age matched control group at 11 years of age, according to asthma and atopy
Healthy
(n = 51)
Atopic
non-asthmatic (n = 29)
P-value Current non-atopic
asthma (n = 5)
P-value Current atopic
asthma (n = 5)
P-value
Boys, n (%) 31 (61) 16 (55) 0.644 4 (80) 0.640 4 (80) 0.640
Age at follow up* (year) 11.8 (11.4, 12.2) 11.4 (11.0, 12.1) 0.081 12.3 (11.4, 12.8) 0.147 11.8 (10.9, 12.0) 0.502
Weight at follow-up† (kg) 41.7 (8.5) 40.9 (9.4) 0.677 47.9 (17.3) 0.472 51.4 (25.7) 0.449
Height at follow-up† (cm) 151.9 (7.6) 149.0 (7.0) 0.087 150.8 (10.2) 0.749 152.0 (17.1) 0.998
ICS, n (%) 1 (2) 0 1.000 3 (60) 0.001 4 (80) <0.001
FEV1%
† 98.7 (10.6) 99.8 (7.9) 0.631 101.9 (10.7) 0.510 96.3 (28.3) 0.864
FEF25–75%
† 96.9 (22.9) 98.9 (16.1) 0.693 95.6 (18.9) 0.903 93.3 (45.7) 0.764
FEV1 /FVC ratio
† 84.3 (6.6) 84.2 (4.5) 0.969 79.8 (4.2) 0.146 80.8 (6.7) 0.269
DRS to methacholine* 1.7 (1.0, 6.8) 3.6 (0.8,17.6) 0.084 0.9 (0.3, 5.8) 0.292 4.7 (1.1, 24.5) 0.405
*Median (inter quartile range), †mean (standard deviation). ICS, inhaled corticosteroids last 12 months before follow up; FEV1%, forced expiratory volume in first
second as percentage of predicted; FEF25–75%, forced expiratory flow between 25-75% of the forced vital capacity (FVC) as percentage of predicted; DRS, dose
response slope. For missing data, see text. P-values assess comparisons with the healthy group.
Bold values indicate significance at the 0.05 level.
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with non-atopic asthma compared to healthy in both
the post-bronchiolitis group and in the control group
(Table 3). Separate analyses for the post-bronchiolitis
and the control group revealed that FeNO was higher
in the atopic non-asthmatic children compared to healthy
in both groups. Higher FeNO in children with atopic
asthma compared to healthy was observed only in the
control group (Table 4, Figure 1).
Regression analyses of potential explanatory factors
for ln FeNO
Atopy, weight and height were positively associated with ln
FeNO by univariate linear regression analyses including allTable 3 Analysis of variance for fractional exhaled nitric
oxide (FeNO) given as ln FeNO in children hospitalized for
bronchiolitis (n = 105) during their first year of life and an
age matched control group (n = 89) at 11 years of age
Variable B* 95% CI P-value†
Main groups
Control group 0 Reference
Post-bronchiolitis group −0.120 −0.309, 0.070 0.214
Sub-groups by atopy
and asthma status
<0.001
Healthy 0 Reference
Atopic non-asthmatic 0.745 0.522, 0.967
Current non-atopic asthma 0.013 −0.308, 0.335
Current atopic asthma 0.651 0.286, 1.102
Intercept‡ 2.131 1.970, 2.291
No significant interaction effects were observed between the variables
post-bronchiolitis/control group and the four subgroups of the study, i.e. the
relationships between FeNO values measured in these four subgroups were
similar in the post-bronchiolitis and the control group.
*Regression coefficient; represents the amount of change of ln NO induced by
a change of 1 unit of the explanatory variable.
†P-values from F test. ‡Reference group (healthy children in the control group).
Bold values indicate significance at the 0.05 level.participating children (Table 5). In the final multivariate
model, atopy, ln DRS and height were independently asso-
ciated with increased ln FeNO (Table 5). No interaction
effects regarding ln FeNO were observed between the var-
iables atopy and current asthma vs. no asthma, meaning
that the associations between atopy and ln FeNO were
similar for the asthmatic and non-asthmatic children and
vice versa (Table 5).
Separate regression analyses were done for children in
the post-bronchiolitis group. By univariate analyses, RSV
negative bronchiolitis, height, FEV1% predicted and atopy
were positively associated with ln FeNO (Table 6). In the
final multivariate model, ln DRS, height and FEV1%
predicted were positively associated with ln FeNO (Table 6).
There was a significant interaction effect between RSV
negative bronchiolitis and atopy, i.e. atopy was posi-
tively associated with FeNO in the RSV negative group
(B = 1.005; 95% CI: 0.496, 1.513; p < 0.001), but not in
the RSV positive group (B = 0.269; 95% CI: -0.071, 0.609;
p = 0.120) Table 6.
There was no significant association between RSV
negative bronchiolitis and atopy (Pearson’s chi square exact
test p =0.304), and there was no association between atopy
and ln DRS (B = 0.173; 95% CI: -0.409, 0.755; p =0.558).
Discussion
In the present study FeNO did not differ between 11 year
old children hospitalized for bronchiolitis in their first
year of life and an age matched control group. Secondly,
atopy and BHR, but not asthma were associated with
FeNO, and these associations were similar in the post-
bronchiolitis and in the control groups.
The guideline from the American Thoracic Society
suggests that levels of FeNO below 20 ppb are less likely
to indicate eosinophilic airway inflammation [2], as also
reported by others [8]. In the present study, the majority of
the FeNO measurements were below this limit. Infantile
Table 4 Levels of fractional exhaled nitric oxide (FeNO) in children hospitalized for bronchiolitis and in an age
matched control group, by asthma and atopic status
Post-bronchiolitis group (n = 105) Control group (n = 89)
N FeNO 95% CI P-values* vs. healthy N FeNO 95% CI P-values* vs. healthy
Healthy 62 8.1 6.8, 9.6 Reference 50 7.6 6.4, 9.1 Reference
Atopic non-asthmatic 20 13.6 10.1, 18.4 0.010 29 19.5 15.6, 24.5 <0.001
Current non-atopic asthma 14 7.2 5.0, 10.4 0.920 5 9.7 5.6, 16.8 0.781
Current atopic asthma 9 12.3 7.8, 19.2 0.237 5 21.4 12.4, 36.9 0.002
Figures are geometric means and 95% confidence intervals (95% CI). FeNO values are given as parts per billion. *Dunnett’s test.
Bold values indicate significance at the 0.05 level.
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inflammation, and a tendency for continued neutrophilic
inflammation in this group of children could conceivably
contribute to the findings of the present study [12].
The association between FeNO and atopy, but not
between FeNO and asthma is in line with several other
studies [3-5]. An association between FeNO and persistent
wheezing has been reported for children less than 2–3 years
of age [23,24], but we could not confirm that this associ-
ation lasts until adolescence. One of these studies did
not adjust for atopy [23], while another study observed
that neither personal nor a family history of atopy was
associated with increased FeNO [24]. Konstantinou et al.
recently described an episodic increase of FeNO during
viral wheezing in 4–6 year old children, independent of the
atopic status of the test-subjects. The increase subsided
after the episodes resolved, rendering wheezers comparable
to non-wheezers outside the wheezing episodes [25].
This is consistent with the low levels of FeNO in the
post-bronchiolitis group in the present study. Others have
reported associations between FeNO and recurrent wheezeHealthy Atopic
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Figure 1 FeNO levels in four different sub-groups of children, split by
as geometric mean with 95% confidence intervals (CI).in infants with an atopic constitution [26] and in atopic
children younger than four years of age [27]. The results
from the present study suggest that also for older children
with a history of infant and preschool viral wheeze, atopy
should be considered as an independent risk factor for
increased FeNO. This is in line with a study from the
Netherlands showing that FeNO can differentiate between
wheezing phenotypes, but only in atopic children [28].
As previously published, lower FEF25–75% predicted,
consistent with small airway obstruction, was observed
in children in the post-bronchiolitis group than children in
the control group [10]. Except for a weak positive associ-
ation between FEV1% and FeNO in the post-bronchiolitis
group, no associations between lung function and FeNO
could be observed. FeNO may predict lung function decline
in adults with severe asthma [29]. However, to our know-
ledge, few studies have found associations between lung
function and FeNO in children [30]. Low levels of FeNO
despite small airway obstruction could indicate structural
explanatory mechanisms and not an ongoing eosinophilic
inflammation [31].rrent
atopic
thma
Current atopic
asthma
Bronchiolitis
Controls
02
bronchiolitis status in their first year of life. FeNO values are given
Table 5 Linear regression model explaining fractional exhaled nitric oxide (FeNO) given as ln FeNO at 11 years of age
in 105 children hospitalized for bronchiolitis and 89 children in an age matched control group, all children analysed
together
Unadjusted models Fully adjusted model (N = 190) Final model (N = 190)
Risk factors B* 95% CI P-value B* 95% CI P-value B* 95% CI P-value
Hospitalization for bronchiolitis −0.200 −0.408, 0.008 0.059 −0.088 −0.276, 0.101 0.359
Male gender −0.131 −0.342, 0.080 0.223
Age at follow up (months) 0.009 −0.006, 0.024 0.257
Height (cm) 0.021 0.007, 0.034 0.002 0.025 0.008, 0.042 0.005 0.027 0.015, 0.038 <0.001
Weight (kg) 0.014 0.004, 0.025 0.009 0.001 −0.012, 0.014 0.849
Atopy 0.736 0.539, 0.934 <0.001 0.757 0.562, 0.951 <0.001 0.773 0.583, 0.962 <0.001
Current asthma 0.035 −0.243, 0.313 0.805
Ln DRS 0.053 −0.003, 0.108 0.062 0.056 0.008, 0.105 0.023 0.051 0.004, 0.097 0.034
FEV1% 0.006 −0.004, 0.016 0.269
FEF25-75% 0.001 −0.003, 0.006 0.597
Use of inhaled steroids preceding 12 months 0.200 −0.169, 0.568 0.287
No interactions were found between current asthma and atopy, atopy and DRS, atopy and hospitalization for bronchiolitis or DRS and hospitalization
for bronchiolitis.
*Regression coefficient, represents the amount of change of ln NO induced by a change of 1 unit of the explanatory variable.
CI, confidence interval; DRS, dose response slope; FEV1%, forced expiratory volume in first second as percentage of predicted; FEF25-75%, forced expiratory flow
between 25-75% of the forced vital capacity.
Bold values indicate significance at the 0.05 level.
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Asthma after bronchiolitis in infancy is heterogeneous
and likely to represent disease entities that differ from
atopic asthma in childhood. RSV is the most common virus
involved in bronchiolitis, but apart from one Swedish study
[32], the risk of asthma after RSV bronchiolitis has not
been linked to atopy [9,11]. An increased risk of asthmaTable 6 Linear regression model explaining fractional exhaled
in 105 children hospitalized for bronchiolitis
Unadjusted models
Risk factors B* 95% CI P-valu
RSV negative bronchiolitis 0.335 0.019, 0.651 0.038
Male gender −0.112 −0.388, 0.164 0.423
Age at follow-up (months) −0.004 −0.277, 0.269 0.977
Height (cm) 0.024 0.005, 0.043 0.015
Weight (kg) 0.015 0.001, 0.030 0.058
Atopy 0.510 0.219, 0.802 0.001
Current asthma −0.033 −0.366 ,0.299 0.977
Ln DRS 0.061 −0.025, 0.148 0.161
FEV1% 0.015 0.000, 0.029 0.044
FEF25–75% 0.002 −0.005, 0.008 0.610
Use of inhaled steroids preceding 12 months 0.003 −0.494, 0.488 0.990
Interaction
RSV negative bronchiolitis × atopy
No interactions were found between current asthma and atopy, atopy and ln DRS o
negative bronchiolitis and atopy, and the final model therefor includes both the int
*Regression coefficient, represents the amount of change of ln NO induced by a ch
CI, confidence interval; DRS, dose response slope; FEV1%, forced expiratory volume
between 25-75% of the forced vital capacity.
Bold values indicate significance at the 0.05 level.after RSV negative vs. RSV positive bronchiolitis has
been reported [10], particularly after RV bronchiolitis
[11]. Wheezing with RV infections has been associated
with atopy [9,33], although we found no association
between atopy and a history of RSV negative bronchiolitis.
Temporarily reduced FeNO has been found in chil-
dren hospitalized for RSV bronchiolitis. Although thenitric oxide (FeNO) given as ln FeNO at 11 years of age
Fully adjusted model (N = 103) Final model (N = 103)
e B* 95% CI P-value B* 95% CI P- value
0.010 −0.337, 0.357 0.957 0.009 −0.336, 0.354 0.958
0.025 0.000, 0.050 0.053 0.024 0.007, 0.041 0.006
−0.001 −0.021, 0.020 0.946
0.269 −0.073, 0.611 0.121 0.269 −0.071, 0.609 0.120
0.094 0.015, 0.173 0.020 0.094 0.017, 0.172 0.018
0.018 0.004, 0.032 0.013 0.018 0.004, 0.031 0.012
0.736 0.125, 1.346 0.019 0.736 0.128, 1.343 0.018
r ln DRS and RSV negative bronchiolitis. There was an interaction between RSV
eraction effect and its main variables (atopy and RSV negative bronchiolitis).
ange of 1 unit of the explanatory variable.
in first second as percentage of predicted; FEF25–75%, forced expiratory flow
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speculated if the absence of eosinophilic inflammation
during the acute bronchiolitis may be involved [34].
The present study showed that previous RSV negative
bronchiolitis was associated with higher FeNO, but
not after adjusting for DRS, atopy and height.
The interaction effect observed between atopy and RSV
negative bronchiolitis may suggest that the influence from
atopy on FeNO is different for children with former RSV
positive than RSV negative bronchiolitis. Our results could
indicate that atopy was more linked to FeNO at 11 years
of age in children with former RSV negative than RSV
positive bronchiolitis. However, the number of participants
was limited and there was a similar and near significant
tendency also for children with a history of RSV positive
bronchiolitis, suggesting that the results should be inter-
preted with caution.
FeNO and bronchial hyperresponsiveness
In the present study, DRS to methacholine was independ-
ently and positively associated with FeNO by the multi-
variate regression analyses including all children and also
in the separate regression analyses including only children
in the post-bronchiolitis group.
A similar association was found by Franklin et al., but
only in atopic children [5]. The Copenhagen birth cohort
study observed an association between FeNO and BHR,
but underlined that this association was independent of
asthma symptoms [35]. We found a similar association
between DRS and FeNO for atopic and non-atopic
children. In the present and in another recent study from
the same population, asthma or atopy was not associated
with BHR, although BHR was higher in the post-
bronchiolitis group [10]. The relationship between NO
metabolism and BHR in asthma is complex [36]. The
ATS guideline underlines that studies report inconsistent
associations and low correlations between FeNO and BHR,
and that BHR, airway inflammation and FeNO belong to
different domains [2]. A Norwegian twin study observed
that common genetic effects could explain the association
between FeNO and BHR, suggesting that FeNO is not
related to BHR per se [37]. Moreover, BHR measured
by direct provocation tests using methacholine or his-
tamine reflects structural airway changes, compared to
indirect provocation tests such as adenosine monopho-
sphate or exercise which probably better reflects airway
inflammation [38].
Strengths and limitations
The main strengths of this study were the prospective
design, the long follow-up period and the high attendance
rate of 82% of those originally included with bronchiolitis.
However, the number of participants in the various
sub-groups was relatively low, reducing the statisticalpower and complicating the interpretations of the results.
This could impact the lack of interaction between the
subgroups and between the post-bronchiolitis and control
groups in the overall ANOVA analysis. In addition, the
number of children in the RSV negative group was small
and the results regarding this group must be interpreted
with caution.
The children in the control group were slightly older
than children in the post-bronchiolitis group at follow-up,
but this should not influence the predicted values regarding
lung function. However, a selection bias among those who
consented cannot be excluded.
RSV was analyzed by direct immunofluorescence and
not based on nucleic acid amplification such as reverse
polymerase chain reaction (PCR). PCR is considered more
sensitive and specific than direct immunofluorescence [39].
Conclusion
In this study, FeNO did not differ between 11 year old
children hospitalized for bronchiolitis in infancy and an
age matched control group. FeNO was associated with
atopy, but not with asthma in both groups of children. This
may suggest that FeNO may be unrelated to the patho-
physiology of asthma after bronchiolitis. The results could
also reflect that airway inflammation is rare in children
11 years after bronchiolitis.
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